FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136016654> ?p ?o ?g. }

• W3136016654 endingPage "1620" @default.
• W3136016654 startingPage "1620" @default.
• W3136016654 abstract "<h3>Importance</h3> Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis. <h3>Objective</h3> To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU). <h3>Design, Setting, and Participants</h3> Multicenter randomized trial with a 2 × 2 factorial design performed in 10 academic centers in Iran comparing intermediate-dose vs standard-dose prophylactic anticoagulation (first hypothesis) and statin therapy vs matching placebo (second hypothesis; not reported in this article) among adult patients admitted to the ICU with COVID-19. Patients were recruited between July 29, 2020, and November 19, 2020. The final follow-up date for the 30-day primary outcome was December 19, 2020. <h3>Interventions</h3> Intermediate-dose (enoxaparin, 1 mg/kg daily) (n = 276) vs standard prophylactic anticoagulation (enoxaparin, 40 mg daily) (n = 286), with modification according to body weight and creatinine clearance. The assigned treatments were planned to be continued until completion of 30-day follow-up. <h3>Main Outcomes and Measures</h3> The primary efficacy outcome was a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days, assessed in randomized patients who met the eligibility criteria and received at least 1 dose of the assigned treatment. Prespecified safety outcomes included major bleeding according to the Bleeding Academic Research Consortium (type 3 or 5 definition), powered for noninferiority (a noninferiority margin of 1.8 based on odds ratio), and severe thrombocytopenia (platelet count <20 ×10³/µL). All outcomes were blindly adjudicated. <h3>Results</h3> Among 600 randomized patients, 562 (93.7%) were included in the primary analysis (median [interquartile range] age, 62 [50-71] years; 237 [42.2%] women). The primary efficacy outcome occurred in 126 patients (45.7%) in the intermediate-dose group and 126 patients (44.1%) in the standard-dose prophylaxis group (absolute risk difference, 1.5% [95% CI, −6.6% to 9.8%]; odds ratio, 1.06 [95% CI, 0.76-1.48];<i>P</i> = .70). Major bleeding occurred in 7 patients (2.5%) in the intermediate-dose group and 4 patients (1.4%) in the standard-dose prophylaxis group (risk difference, 1.1% [1-sided 97.5% CI, −∞ to 3.4%]; odds ratio, 1.83 [1-sided 97.5% CI, 0.00-5.93]), not meeting the noninferiority criteria (<i>P</i>for noninferiority >.99). Severe thrombocytopenia occurred only in patients assigned to the intermediate-dose group (6 vs 0 patients; risk difference, 2.2% [95% CI, 0.4%-3.8%];<i>P</i> = .01). <h3>Conclusions and Relevance</h3> Among patients admitted to the ICU with COVID-19, intermediate-dose prophylactic anticoagulation, compared with standard-dose prophylactic anticoagulation, did not result in a significant difference in the primary outcome of a composite of adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days. These results do not support the routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients admitted to the ICU with COVID-19. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT04486508" @default.
• W3136016654 created "2021-03-29" @default.
• W3136016654 creator A5000847243 @default.
• W3136016654 creator A5001986371 @default.
• W3136016654 creator A5003476734 @default.
• W3136016654 creator A5010466750 @default.
• W3136016654 creator A5012638668 @default.
• W3136016654 creator A5014735011 @default.
• W3136016654 creator A5017355704 @default.
• W3136016654 creator A5021368492 @default.
• W3136016654 creator A5023217339 @default.
• W3136016654 creator A5023251356 @default.
• W3136016654 creator A5026788917 @default.
• W3136016654 creator A5027668268 @default.
• W3136016654 creator A5032541158 @default.
• W3136016654 creator A5033100094 @default.
• W3136016654 creator A5034309266 @default.
• W3136016654 creator A5034870289 @default.
• W3136016654 creator A5036458544 @default.
• W3136016654 creator A5038208784 @default.
• W3136016654 creator A5038405190 @default.
• W3136016654 creator A5038723268 @default.
• W3136016654 creator A5040301840 @default.
• W3136016654 creator A5040747795 @default.
• W3136016654 creator A5041107362 @default.
• W3136016654 creator A5042924400 @default.
• W3136016654 creator A5043824336 @default.
• W3136016654 creator A5045390831 @default.
• W3136016654 creator A5045688475 @default.
• W3136016654 creator A5046629853 @default.
• W3136016654 creator A5047198456 @default.
• W3136016654 creator A5047412968 @default.
• W3136016654 creator A5054972036 @default.
• W3136016654 creator A5055256745 @default.
• W3136016654 creator A5055657448 @default.
• W3136016654 creator A5056521643 @default.
• W3136016654 creator A5058421055 @default.
• W3136016654 creator A5058875978 @default.
• W3136016654 creator A5059050074 @default.
• W3136016654 creator A5059807691 @default.
• W3136016654 creator A5063628237 @default.
• W3136016654 creator A5065894925 @default.
• W3136016654 creator A5067537047 @default.
• W3136016654 creator A5070342699 @default.
• W3136016654 creator A5070409619 @default.
• W3136016654 creator A5070557401 @default.
• W3136016654 creator A5070888107 @default.
• W3136016654 creator A5070895986 @default.
• W3136016654 creator A5071884302 @default.
• W3136016654 creator A5072094133 @default.
• W3136016654 creator A5075356019 @default.
• W3136016654 creator A5075440850 @default.
• W3136016654 creator A5075791833 @default.
• W3136016654 creator A5077468662 @default.
• W3136016654 creator A5080423987 @default.
• W3136016654 creator A5080853570 @default.
• W3136016654 creator A5080919013 @default.
• W3136016654 creator A5082773117 @default.
• W3136016654 creator A5087662144 @default.
• W3136016654 creator A5087928566 @default.
• W3136016654 creator A5088028306 @default.
• W3136016654 creator A5088466083 @default.
• W3136016654 date "2021-04-27" @default.
• W3136016654 modified "2023-10-16" @default.
• W3136016654 title "Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit" @default.
• W3136016654 cites W2122779695 @default.
• W3136016654 cites W2418821229 @default.
• W3136016654 cites W2799773951 @default.
• W3136016654 cites W2922149602 @default.
• W3136016654 cites W2981042936 @default.
• W3136016654 cites W3014294089 @default.
• W3136016654 cites W3015863623 @default.
• W3136016654 cites W3017326650 @default.
• W3136016654 cites W3020168167 @default.
• W3136016654 cites W3021954309 @default.
• W3136016654 cites W3023873927 @default.
• W3136016654 cites W3024193040 @default.
• W3136016654 cites W3026400664 @default.
• W3136016654 cites W3027329842 @default.
• W3136016654 cites W3027918021 @default.
• W3136016654 cites W3028989873 @default.
• W3136016654 cites W3030604488 @default.
• W3136016654 cites W3041992145 @default.
• W3136016654 cites W3043015313 @default.
• W3136016654 cites W3045413314 @default.
• W3136016654 cites W3080389823 @default.
• W3136016654 cites W3082108964 @default.
• W3136016654 cites W3082240102 @default.
• W3136016654 cites W3082355253 @default.
• W3136016654 cites W3087656790 @default.
• W3136016654 cites W3088000334 @default.
• W3136016654 cites W3092513774 @default.
• W3136016654 cites W3094167898 @default.
• W3136016654 cites W3103284476 @default.
• W3136016654 cites W3107851654 @default.
• W3136016654 cites W3108572624 @default.
• W3136016654 cites W3126061642 @default.
• W3136016654 cites W3128604271 @default.

• next